Summit Therapeutics (SMMT) Intangibles (2017 - 2022)

Summit Therapeutics (SMMT) has 6 years of Intangibles data on file, last reported at $8.0 million in Q3 2022.

• Quarterly Intangibles fell 25.04% year-over-year to $8.0 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $8.0 million (down 25.04% YoY) and the FY2021 annual result came in at $10.4 million, down 9.69% from the prior year.
• Intangibles declined to $8.0 million in Q3 2022, from $8.9 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $20.4 million in Q2 2018 to a low of $4.4 million in Q3 2018.
• A 5-year average of $12.0 million and a median of $11.4 million in 2020 frame the typical range for Intangibles.
• Annual changes were most pronounced in 2018 — Intangibles soared 362.63% — and 2019, when it slumped 31.78%.
• Tracing SMMT's Intangibles over 5 years: stood at $14.1 million in 2018, then decreased by 9.0% to $12.8 million in 2019, then decreased by 9.99% to $11.5 million in 2020, then decreased by 9.69% to $10.4 million in 2021, then decreased by 23.53% to $8.0 million in 2022.
• The last three Intangibles figures came in at $8.0 million (Q3 2022), $8.9 million (Q2 2022), and $9.9 million (Q1 2022), per Business Quant data.